Get the Stockscreener App
10.49
0.77%
0.0799
Vir Biotechnology Inc stock is traded at $10.49, with a volume of 746.17K.
It is up +0.77% in the last 24 hours and up +0.48% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$10.41
Open:
$10.38
24h Volume:
746.17K
Relative Volume:
0.30
Market Cap:
$1.78B
Revenue:
$68.56M
Net Income/Loss:
$-437.99M
P/E Ratio:
-3.3155
EPS:
-3.1639
Net Cash Flow:
$-396.61M
1W Performance:
-5.67%
1M Performance:
+0.48%
6M Performance:
+0.29%
1Y Performance:
+72.82%
1-Day Range:
$10.20
$10.57
1-Week Range:
$10.34
$12.00
52-Week Range:
$4.815
$12.00
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.49 | 1.78B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Can Vir Biotechnology (NASDAQ:VIR) Keep Climbing After Latest Target Boost? - Kalkine Media
Aziz Sawaf, CFO of Vir Biotechnology (VIR), reports zero directly held common shares. - Stock Titan
One talk will cover hepatitis D response data through 96 weeks; another will study liver immune cells. - Stock Titan
A $150K sign-on bonus, contingent on continued employment, awaits Vir Biotechnology (VIR)'s incoming CFO. - Stock Titan
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Nears Key Hepatitis Delta Readout - kalkinemedia.com
Vir Biotechnology (NasdaqGS:VIR) Stock Forecast & Analyst Predictions - Simply Wall Street
Vir Biotechnology Stock Price Forecast. Should You Buy VIR? - StockInvest.us
Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Former Vir (NASDAQ: VIR) officer sold $315K in stock, with more share sales planned - Stock Titan
WINTON GROUP Ltd Trims Stake in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (VIR) ex-officer to sell 28,333 shares from option exercise - Stock Titan
How (VIR) Movements Inform Risk Allocation Models - Stock Traders Daily
Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology stock gains on conference catalyst - ad-hoc-news.de
Man Group plc Takes $1.54 Million Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology stock gains on new 52-week high and conference appearance - ad-hoc-news.de
Corient Private Wealth LP Invests $3.17 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week HighShould You Buy? - MarketBeat
Vir Biotechnology stock gains on conference participation and 52-week high - ad-hoc-news.de
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com Canada
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com India
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com Nigeria
Vir Biotechnology stock hits 52-week high at 11.66 USD - investing.com
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com UK
Vir Biotechnology (NASDAQ:VIR) Trading 4.8% HigherHere's What Happened - MarketBeat
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire
Vir Biotechnology CEO to speak at Morgan Stanley conference Sept. 14 - Stock Titan
Deutsche Bank AG Acquires Shares of 134,258 Vir Biotechnology, Inc. $VIR - MarketBeat
ARCH Venture Management LLC Invests $129.35 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (NASDAQ: VIR) ex-officer lines up more sales - Stock Titan
Vir Biotechnology (NASDAQ:VIR) Shares Up 8.1%Time to Buy? - MarketBeat
Vir Biotechnology (NASDAQ: VIR) officer plans 14,352-share sale after 25K sale - Stock Titan
Vir Biotechnology (NASDAQ: VIR) ex-officer files notice for potential $245K stock sale - Stock Titan
Vir Biotechnology on Track for Record Winning Streak -- Data Talk - Bitget
Vir (VIR) Close and Levels: Adds 1.06% to Close at $9.49 in the Latest Reading; Key Levels: the $9.02 to $9.96 Range Remains in Focus in Latest TradingRevenue Weighted - vinanet.vn
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - Sahm
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum - TipRanks
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - simplywall.st
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - simplywall.st
Vir Biotechnology (VIR) Climbs 2.67% to $9.24 as Trading Volume Picks UpETH Profile - vinanet.vn
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo Finance
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - AOL.com
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vir Biotechnology Inc Stock (VIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'Byrne Jason | Former Officer |
Sep 09 '26 |
Proposed Sale |
11.13 |
28,333 |
315,241 |
0 |
| O'Byrne Jason | Former Officer |
Aug 25 '26 |
Proposed Sale |
10.48 |
23,148 |
242,591 |
0 |
| O'Byrne Jason | Former Officer |
Aug 24 '26 |
Proposed Sale |
9.90 |
14,352 |
142,124 |
0 |
| O'Byrne Jason | Former Officer |
Aug 21 '26 |
Proposed Sale |
9.81 |
25,000 |
245,297 |
0 |
| Ramasastry Saira | Former Director |
Jun 29 '26 |
Proposed Sale |
10.32 |
16,000 |
165,139 |
0 |
| Napolitano Janet | Director |
Jun 01 '26 |
Sale |
9.45 |
3,200 |
30,240 |
21,216 |
| Sabatini Brent | SVP, Chief Accounting Officer |
Jun 01 '26 |
Sale |
9.45 |
379 |
3,582 |
61,902 |
| Sabatini Brent | Officer |
Jun 01 '26 |
Proposed Sale |
9.45 |
379 |
3,582 |
0 |
| Napolitano Janet | Director |
Jun 01 '26 |
Proposed Sale |
9.45 |
3,200 |
30,240 |
0 |
| SATO VICKI L | Director |
May 01 '26 |
Sale |
10.05 |
22,000 |
221,025 |
1,078,391 |
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):